Moderna COVID-19 vaccine was “94.5% effective” in preventing coronavirus disease.
Moderna Inc. on Monday said that the experimental COVID-19 vaccine was “94.5% effective” in preventing the coronavirus disease based on interim data from a late-stage trial.
This, as the company became the second drugmaker in the United States to report results that far exceeded expectations — the first was a jointly-developed COVID-19 vaccine from Pfizer and BioNTech.
With this, the United States could have two COVID-19 vaccines authorized for “emergency use” in December with as many as 60 million doses of COVID-19 vaccine available this year.
In 2021, the US government could have access to over 1 billion doses just from the two COVID-19 vaccine makers, more than needed for 330 million residents in the United States.
The COVID-19 vaccines, both developed with new technology known as “messenger RNA (mRNA)”, represented powerful tools in order to fight a pandemic that had infected over 54 million people worldwide and killed more than 1.3 million.
In addition, the news also came at time when COVID-19 cases were increasing, hitting new records in the US and pushing some European countries back into lockdowns.
READ ALSO: Sputnik V COVID-19 Vaccine ‘More Than 90%’ Effective, Says Russia’s Health Ministry
In a telephone interview, Moderna President Stephen Hoge said that they’re going to have a vaccine that could stop COVID-19.
Reuters reported that the interim analysis of Moderna was based on 95 infections among trial participants who received either the vaccine or a placebo.
As per the report, only five of those infections occurred in those who received the COVID-19 vaccine, which was administered in two shots 28 days apart.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via official Facebook page and YouTube channel.